MY181685A - Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer - Google Patents

Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Info

Publication number
MY181685A
MY181685A MYPI2016704048A MYPI2016704048A MY181685A MY 181685 A MY181685 A MY 181685A MY PI2016704048 A MYPI2016704048 A MY PI2016704048A MY PI2016704048 A MYPI2016704048 A MY PI2016704048A MY 181685 A MY181685 A MY 181685A
Authority
MY
Malaysia
Prior art keywords
resveratrol
diabetes
cancer
compositions
methods
Prior art date
Application number
MYPI2016704048A
Other languages
English (en)
Inventor
J Slaga Thomas
Junco Jacob
Liang Huiyun
Reyna Sara
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MY181685A publication Critical patent/MY181685A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2016704048A 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer MY181685A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461988859P 2014-05-05 2014-05-05

Publications (1)

Publication Number Publication Date
MY181685A true MY181685A (en) 2020-12-31

Family

ID=54392898

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016704048A MY181685A (en) 2014-05-05 2015-05-05 Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

Country Status (6)

Country Link
US (7) US10155003B2 (enExample)
EP (1) EP3139910B1 (enExample)
JP (2) JP6716468B2 (enExample)
AU (2) AU2015256178B2 (enExample)
MY (1) MY181685A (enExample)
WO (1) WO2015171598A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015256178B2 (en) * 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
WO2017080958A1 (en) * 2015-11-13 2017-05-18 Unilever Plc Composition for hair follicle growth
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2019011293A1 (zh) 2017-07-13 2019-01-17 华东理工大学 靶向于pd-1的皂苷类化合物及其应用
EP3681507B8 (en) * 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
US20250295615A1 (en) * 2021-11-18 2025-09-25 Board Of Regents, The University Of Texas System Combinations of curcumin and ursolic acid and uses thereof
KR102991532B1 (ko) * 2023-09-06 2026-07-20 바이오스펙트럼 주식회사 천연 화합물을 포함하는 비만 및/또는 대사성 질환의 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
CN101516364B (zh) * 2006-07-14 2011-12-28 帝斯曼知识产权资产管理有限公司 组合物及其用于治疗、共治疗或预防炎性病症的用途
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
CN101032564B (zh) * 2007-02-28 2011-03-23 天津津酒集团有限公司 调节血脂养生酒及其制备方法
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
AU2011240690C1 (en) * 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
US9393221B2 (en) * 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage
WO2014014530A1 (en) 2012-07-17 2014-01-23 Mylari Banavara L Ursolic acid salts for treating diabetes and obesity
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
AU2015256178B2 (en) * 2014-05-05 2020-02-27 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
KR20250008786A (ko) * 2014-07-29 2025-01-15 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법

Also Published As

Publication number Publication date
US20190192537A1 (en) 2019-06-27
US11166962B2 (en) 2021-11-09
US20220023241A1 (en) 2022-01-27
US20170056414A1 (en) 2017-03-02
AU2020203419A1 (en) 2020-06-11
US10155003B2 (en) 2018-12-18
EP3139910B1 (en) 2019-11-27
US20210252016A1 (en) 2021-08-19
EP3139910A4 (en) 2017-11-29
US20220226347A1 (en) 2022-07-21
WO2015171598A1 (en) 2015-11-12
US20200330480A1 (en) 2020-10-22
JP2020147590A (ja) 2020-09-17
US10583145B2 (en) 2020-03-10
US11090311B2 (en) 2021-08-17
US20200323879A1 (en) 2020-10-15
EP3139910A1 (en) 2017-03-15
JP2017514858A (ja) 2017-06-08
JP6716468B2 (ja) 2020-07-01
US11642354B2 (en) 2023-05-09
US11684626B2 (en) 2023-06-27
AU2020203419B2 (en) 2021-05-13
US11690851B2 (en) 2023-07-04
AU2015256178B2 (en) 2020-02-27
AU2015256178A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
IL273058A (en) Compositions and methods for modulation of PKK expression
MX2020014120A (es) Agonistas parciales del receptor de insulina.
PH12016501763A1 (en) Multispecific antibodies
GEP20217331B (en) Anti-tigit antibodies
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
SMT202300445T1 (it) Metodi e composizioni per trattare l’obesità, prevenire l’aumento di peso, promuovere la perdita di peso, promuovere il dimagrimento, o trattare o prevenire lo sviluppo del diabete
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
EP3226972A4 (en) Methods and compositions for treating migraine and conditions associated with pain
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
ZA201702720B (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EP3139910A4 (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
HUE040167T2 (hu) Rákkezelés
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
MX2015013021A (es) 5-bromo-indirrubinas.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
PH12017501897A1 (en) 2-thiopyrimidinones
ZA201608406B (en) Enzyme treatment composition
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA103980C2 (ru) Способ консервативного лечения апоплексии яичника с минимальным гемоперитонеумом
TR201401753A2 (tr) Nekroz tedavisine yönelik bir kompozisyon.